No Data
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
Progyny's Strong Results Overshadowed by ART Cycle Decline and Core Business Uncertainty
Progyny Price Target Cut to $21.00/Share From $23.00 by Canaccord Genuity
Progyny Is Maintained at Hold by Canaccord Genuity
Canaccord Genuity Maintains Hold on Progyny, Lowers Price Target to $21
Progyny Analyst Ratings